Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3289186 | 0.84 | PTGS1 (0.58) | PTGS2PTGS1PDPK1KDM4EALDH1A1 | |
| SCHEMBL22122152 | 0.81 | PTGS2 (0.52) | PTGS2PTGS1PDPK1KDM4EALDH1A1 | |
| SCHEMBL22122126 | 0.81 | PTGS2 (0.43) | PTGS2PTGS1PDPK1KDM4EALDH1A1 | |
| SCHEMBL7319092 | 0.79 | PTGS1 (0.60) | PTGS2PTGS1PDPK1MAPTCYP2C9 | |
| SCHEMBL3277337 | 0.78 | PTGS2 (0.55) | PTGS2PTGS1KDM4EALDH1A1MAPT | |
| SCHEMBL7242014 | 0.76 | PTGS2 (0.53) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL14887387 | 0.76 | PTGS2 (0.57) | PTGS2PTGS1PDPK1MAPTALOX15 | |
| SCHEMBL7323665 | 0.76 | PTGS2 (0.53) | PTGS2PTGS1PDPK1CYP2C9 | |
| SCHEMBL18865526 | 0.76 | PDPK1 (0.53) | PTGS2PTGS1PDPK1 | |
| SCHEMBL14659371 | 0.75 | TRPV1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010044445-A1 | AZOLE INHIBITORS OF CYTOKINE PRODUCTION | ABBOTT LABORATORIES | 2001-11-22 | — | — | US | disclosed |
| EP-1068187-A1 | PYRAZOLE INHIBITORS OF CYTOKINE PRODUCTION | ABBOTT LABORATORIES (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999051580-A1 | PYRAZOLE INHIBITORS OF CYTOKINE PRODUCTION | ABBOTT LABORATORIES (US) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044445-A1 | AZOLE INHIBITORS OF CYTOKINE PRODUCTION | IL5, IL2, IL4 | PTGS2 158/4885PTGS1 197/4885PDPK1 3706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.